HIV-1 capsids from B27/B57+ elite controllers escape Mx2 but are targeted by TRIM5α, leading to the induction of an antiviral state

PLoS Pathog. 2018 Nov 12;14(11):e1007398. doi: 10.1371/journal.ppat.1007398. eCollection 2018 Nov.

Abstract

Elite controllers (ECs) are a rare subset of HIV-1 slow progressors characterized by prolonged viremia suppression. HLA alleles B27 and B57 promote the cytotoxic T lymphocyte (CTL)-mediated depletion of infected cells in ECs, leading to the emergence of escape mutations in the viral capsid (CA). Whether those mutations modulate CA detection by innate sensors and effectors is poorly known. Here, we investigated the targeting of CA from B27/B57+ individuals by cytosolic antiviral factors Mx2 and TRIM5α. Toward that aim, we constructed chimeric HIV-1 vectors using CA isolated from B27/B57+ or control subjects. HIV-1 vectors containing B27/B57+-specific CA had increased sensitivity to TRIM5α but not to Mx2. Following exposure to those vectors, cells showed increased resistance against both TRIM5α-sensitive and -insensitive HIV-1 strains. Induction of the antiviral state did not require productive infection by the TRIM5α-sensitive virus, as shown using chemically inactivated virions. Depletion experiments revealed that TAK1 and Ubc13 were essential to the TRIM5α-dependent antiviral state. Accordingly, induction of the antiviral state was accompanied by the activation of NF-κB and AP-1 in THP-1 cells. Secretion of IFN-I was involved in the antiviral state in THP-1 cells, as shown using a receptor blocking antibody. This work identifies innate activation pathways that are likely to play a role in the natural resistance to HIV-1 progression in ECs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents
  • Antiviral Restriction Factors
  • CD8-Positive T-Lymphocytes / immunology
  • Capsid / metabolism
  • Capsid / physiology
  • Carrier Proteins / metabolism*
  • Epitopes, T-Lymphocyte / immunology
  • Female
  • HIV Infections / immunology
  • HIV Seropositivity
  • HIV-1 / genetics*
  • HIV-1 / immunology
  • HLA-B Antigens / genetics
  • HLA-B27 Antigen / genetics
  • Humans
  • Male
  • Myxovirus Resistance Proteins / metabolism*
  • T-Lymphocytes, Cytotoxic / immunology
  • Tripartite Motif Proteins
  • Ubiquitin-Protein Ligases
  • Viremia
  • Virus Replication / immunology

Substances

  • Antiviral Agents
  • Antiviral Restriction Factors
  • Carrier Proteins
  • Epitopes, T-Lymphocyte
  • HLA-B Antigens
  • HLA-B27 Antigen
  • HLA-B57 antigen
  • MX2 protein, human
  • Myxovirus Resistance Proteins
  • Tripartite Motif Proteins
  • TRIM5 protein, human
  • Ubiquitin-Protein Ligases

Grants and funding

This research received support from the AIDS and infectious disease network of the Fonds de Recherche du Québec - Santé (FRQS) (http://www.frqs.gouv.qc.ca/en/la-recherche/la-recherche-financee-par-le-frqs/centres-groupes-et-reseaux/groupe?id=qdo2gjrq1401198373716), the Canadian Institutes of Health Research (CIHR) to LB (MOP-102712, 370954) and to CT (MOP-93770, TCO-125276) (http://www.cihr-irsc.gc.ca/e/49857.html) and the MITACS Globalink program (http://www.mitacs.ca/en/programs/globalink/globalink-research-award). NMe received postdoctoral fellowships from CIHR and from FRQS. CD is the recipient of a CIHR Canada Graduate Scholarships-Master’s Program award and a Master’s training scholarship from FRQS. JXL was supported by the MITACS Globalink program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.